CiToxLAB emerges from CIT and LAB Research merger

Will provide pre-clinical and specialist services from four facilities

The newly established group created through the merger of CIT and LAB Research will be called CiToxLAB and provide a comprehensive range of pre-clinical and specialist services from four facilities in France, Canada, Denmark and Hungary.

With combined revenues in excess of US$100m, and more than 800 employees, the new group claims to be a major global player in the preclinical outsourcing arena.

’We are confident that this merger will make CiToxLAB an even more attractive partner for our traditional pharmaceutical and biotech clients,’ said group president Jean-Francois Le Bigot. ‘We can offer all the benefits of local, smart-sized facilities, backed up by global resources.’

Le Bigot added that CiToxLAB’s size and capacities also allow the company to offer turnkey solutions.

‘From a single point of entry into the group, we can offer Big Pharma global packages in preclinical testing, seamlessly coordinated by our project managers,’ he said.

CiToxLAB comprises:

  • CiToxLAB France, with 320 staff, 20,000m2 facilities and 40 years’ experience, offers general toxicology studies, reproductive toxicology, carcinogenicity studies, transgenic models, DMPK, bioanalysis, safety pharmacology, TCR (Tissue Cross Reactivity), toxicogenomics and the Leadscreen programme. The facility has special expertise in NHP toxicology, bone metabolism, nasal administration and immunotoxicology.
  • CiToxLAB North America, with 200 staff, 16,000m2 facilities and 13 years’ experience, offers general toxicology studies (including in NHP), reproductive toxicology, DMPK, bioanalysis, immunology services and safety pharmacology. The facility specialises in radiation safety, efficacy studies, infusion and inhalation administration.

  • CiToxLAB Scantox (Denmark), with 155 staff, 9,000m2 facilities and 34 years’ experience, offers general toxicology studies, reproductive toxicology (including in minipigs), carcinogenicity testing, bioanalysis and genetic toxicology.

  • CiToxLAB Hungary, with 130 staff, 15,000m2 facilities and 40 years’ experience, offers general toxicology and inhalation toxicology studies, ecotoxicology and environmental fate studies and a broad range of studies for the registration of chemicals under REACH legislation.

Through associate companies and partners such as Atlanbio (St-Nazaire, France), Stemina (Madison, USA) and Biomodels (Boston, USA), CiToxLAB can offer access to further services such as clinical bioanalysis, embryonic stem cell biomarker discovery and customised preclinical efficacy models.

Companies